Evidence map›Paper›PMID 10516068›Full record

ArticleJournal of virology1999

A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.

N Srinivasakumar, F G Schuening

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
  3. Article
  4. Replication-competent lentivirus analysis of clinical grade vector products.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Article
  5. Article
  6. Transfection of nerve cells.Neuroscience and behavioral physiology · 2010
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

N SrinivasakumarBone Marrow Transplant Program, Department of Medicine, University of Wisconsin, Madison, USA.
F G Schuening
University of Wisconsin–Madison · US

Funding

IDURONIDASE GENE TRANSFER INTO HEMATOPOIETIC CELLSR01DK048265 · NIDDK · VANDERBILT UNIVERSITY · PI SCHUENING, FRIEDRICH G · 1994 to 2004
$1.2M
FACTORS AFFECTING GENE DELIVERY OF HIV1 VECTORSR01DK053929 · NIDDK · VANDERBILT UNIVERSITY · PI KUMAR, SRINIVAS NARASIMHACHAR · 1999 to 1999
–
FACTORS AFFECTING GENE DELIVERY OF HIV1 VECTORSR21DK053929 · NIDDK · UNIVERSITY OF WISCONSIN MADISON · PI KUMAR, SRINIVAS NARASIMHACHAR · 1998 to 1999
–
NIDDK NIH HHS R01 DK048265NIDDK NIH HHS R01 DK48265NIDDK NIH HHS R29 DK53929
6 · The paper itself

Abstract

A lentivirus-based packaging system was designed to reduce the chance of recombination between helper and gene transfer vector sequences by using the constitutive transport element (CTE) derived from Mason-Pfizer monkey virus for expression of the viral proteins and the Rev-Rev response element (RRE) combination for expression of the gene transfer vector. Using this approach, we evaluated a series of human immunodeficiency virus type 1 packaging constructs that express one or more accessory proteins (Vif, Vpr, and Vpu), in addition to the Gag and Pol proteins, for particle formation and virus stock production for gene transfer. Constructs that also express Vpr or both Vpr and Vpu produced more particles, as measured by a p24 assay, than did plasmids that did not contain these sequences. Transactivation experiments showed that the packaging plasmids that encode Vpr or both Vpr and Vpu also expressed a functional single-exon Tat protein. For these constructs, high-titer virus stocks could be prepared in the absence of a cotransfected Tat-expressing plasmid. Amphotropic-envelope-pseudotyped virus stocks prepared with all of the packaging constructs, irrespective of whether any of the accessory proteins were coexpressed, were equally efficient in transducing growth-arrested HeLa cells. The combination/mixed packaging system was compared to systems that were based on either the CTE alone or Rev and RRE for expression of both the packaging plasmid as well as the gene transfer vector. The combination/mixed packaging system was comparable to the other systems for production of virus stocks, suggesting that this design may prove to be safer for the eventual deployment of lentivirus vectors for therapeutic purposes.

Indexed as

Genetic VectorsGene Transfer TechniquesGene ExpressionHeLa CellsHIV-1HumansResponse ElementsRNA, ViralTranscriptional ActivationTransgenesViral Regulatory and Accessory ProteinsVirionVirus AssemblyRNA, ViralViral Regulatory and Accessory Proteins

Identifiers

PMID10516068
PMCPMC112994
OpenAlexW2118347229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.